Influence of highly active antiretroviral treatment (HAART) on risk factors for vertical HIV transmission

Acta Obstetricia et Gynecologica Scandinavica

Volumn 88, Issue 8, 2009, Pages 882-887

  Garcia Tejedor, Amparo ^a   Maiques, Vicente ^a   Perales, Alfredo ^a   Lpez Aldeguer, Jose ^a  

^a HOSPITAL INFANTIL LA FE   (Spain)

Author keywords

HAART; High risk pregnancy; HIV; Vertical transmission

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; BIRTH WEIGHT; CD4 LYMPHOCYTE COUNT; CESAREAN SECTION; CLINICAL EVALUATION; COHORT ANALYSIS; DELIVERY; FEMALE; HIGH RISK PREGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAPARTUM CARE; INVASIVE PROCEDURE; LABOR; MAJOR CLINICAL STUDY; MATERNAL CARE; MODULATION; MONOTHERAPY; OBSTETRIC CARE; PERINATAL PERIOD; PREGNANT WOMAN; PREMATURE FETUS MEMBRANE RUPTURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SPAIN; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; DISEASE TRANSMISSION; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; RETROSPECTIVE STUDY; STATISTICAL MODEL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LOGISTIC MODELS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD;

EID: 68249141866     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340903062836     Document Type: Article

References (24)

1. Working Group on Mother-to-Child Transmission of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 8: 506-10.
2. Connor EM, Sperling RS, Gelber R, Kiseley P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. New Engl J Med. 1994;/331:/1173-80.
3. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Perinatal HIV Guidelines Working Group. 2008. Available online at: http://AID Sinfo.nih.gov.
4. Minkoff H, Ahdieh L, Watts DH, Greenblatt R, Schmidt J, Schneider M, et al. The relationship of pregnancy to the use of highly active antiretroviral therapy. Am J Obstet Gynecol. 2001;/184:/1221-7.
5. Mandelbrot L, Le Chenadec J, Berrebi A, Bongain A, Benifla JL, Delfraissy JF, et al. for the French Perinatal Cohort. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French perinatal cohort. JAMA 1998; 280: 55-60.
6. Cadwell MB, Oxtoby MJ, Simonds RJ, Lindegren ML, Rogers MF. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep. 1994;/43:/1-10.
7. García-Tejedor A, Perales A, Maiques V. Duration of ruptured membranes and/or labor as risk factors for HIV transmission. Int J Gynecol Obstet. 2003;/82:/17-23.
8. García-Tejedor A. HIV perinatal transmission. Virus load impact. Doctoral thesis, Faculty of Medicine, Valencia, Spain, May 2002.
9. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007;/21:/1019-26.
10. Maiques V, García-Tejedor A, Perales A, Navarro C. Intrapartum fetal invasive procedures and perinatal transmission of HIV. Eur J Obstet Gynecol Reprod Biol. 1999;/87:/ 63-7.
11. Van Dyke RB, Korber BT, Popek E, Macken C, Widmayer SM, Bardeguez A, et al. and the Ariel Core Investigators. The Ariel Project: a prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J Infect Dis. 1999; 179: 319-28.
12. Shapiro DE, Sperling RS, Mandelbrot L, Britto P, Cunningham BE, for the pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Risk factors for perinatal human immunodeficiency virus transmission in patients receiving zidovudine prophylaxix. Obstet Gynecol. 1999; 94: 897-908.
13. Viscarello RR, Cullen MT, DeGenaro NJ, et al. Is the rate of perinatal transmission of HIV-1 increased by amniocentesis. Am J Obstet Gynecol. 1994; 170 [Abstract no 1].
14. Maiques V, García-Tejedor A, Perales A, Córdoba J, Esteban RJ. HIV detection in amniotic fluid samples. Amniocentesis can be performed in HIV pregnant women? Eur J Obstet Gynecol Reprod Biol. 2003;/108:/138-42.
15. Minkoff H, Burns DN, Landesman S, Youchach J, Goedert JJ, Nugent RP, et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol. 1995; 173: 585-9.
16. Welles SL, Pitt J, Colgrove R, et al. for the Women and Infants Transmission Study Group. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study. AIDS. 2000;/14:/263-71.
17. Mofenson LM. Short-course zidovudine for prevention of perinatal infection. Lancet. 1999;/353:/766-7.
18. The European Mode of Delivery Collaboration. Elective caesarean section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353: 1035-39.
19. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340: 977-87.
20. European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13: 1377-85.
21. Sperling RS, Shapiro DE, McSherry GD, Britto P, Cunningham BE, Culnane M, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trials Group 076 study. AIDS 1998; 12: 1805-13.
22. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998; 12: F241-F247.
23. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-9. (Pubitemid 29452821)
24. García-Tejedor A, Perales A, Maiques V. Protease inhibitor treatment in HIV pregnant women. Is it safe for newborns? Int J Gynecol Obstet. 2002;/76:/175-6.